Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
Jordan Goldstein(Stanford University), Ash A. Alizadeh(California Institute for Regenerative Medicine), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Sandra Close(Eli Lilly (United States)), Mark Roschewski(National Cancer Institute), Wyndham H. Wilson(National Institutes of Health), David M. Kurtz(Stanford University), Stefan Alig(Heidelberg University), Sang Eun Yoon(Sungkyunkwan University), Jacob J. Chabon(Foresight Science & Technology (United States)), Won-Seog Kim(Samsung Medical Center), Ryan C. Lynch(Seattle Cancer Care Alliance), Seok Jin Kim(Samsung Medical Center), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 1
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k